New Market Report Now Available: Slovenia Pharmaceuticals & Healthcare Report Q3 2010

June 10, 2010 - PRLog -- In BMI's Business Environment Ratings (BER) table for Q310, Slovenia is ranked 10th of the 20 markets assessed in the Emerging Europe region, down by one place in relation to the previous quarter. Globally, Slovenia is ranked 38th out of 82 markets.

The regional average score for Emerging Europe has improved steadily in recent quarters and stands at 51 for Q310. In Q210 it reached 49.4, up from 48.7 in Q209. Globally, however, Emerging Europe remains the second-least attractive market, with only the Middle East & Africa (MEA) considered less attractive to multinationals.

Overall, Slovenia's attractiveness suffers from a small market size; however, it benefits from location and EU membership, which will help with exports.

In March the Slovenian government approved a draft Health Services Act. This act lays the groundwork for system reform in the country and reorganises the provision of healthcare services and introduces new quality assurance systems. Improving regulations will increase Slovenia's attractiveness to multinationals. The Slovenian healthcare system currently consists of three main pillars - primary care (basic outpatient health and pharmacy services), secondary care (more complex healthcare, including in-patient services) and tertiary care (most demanding forms of ambulatory and hospital-based treatments). Under the new act community health centres will take responsibility for: coordinating and providing services in primary care; the re-classification and reorganisation of hospitals; introduction of joint provision of individual specialities in both primary and secondary care; and increased regulations on private care in the public sector setting, including retaining revenues within the public institute.

Also in March, Lek, part of Novartis's generic arm Sandoz, has opened a US$3.8mn biopharmaceutical production facility to produce biosimilar epoetin alfa. Sandoz markets epoetin alfa under the trade names Binocrit and Epoetin alfa Hexal in the EU (following approval from the European Medicines Agency (EMA) approval in 2007). This facility should help meet the increasing demand for biosimilars primarily in the EU and other emerging Europe markets and should boost Slovenian exports.

Novartis has invested EUR900mn in Slovenia since the purchase of Lek in 2002 and the new facility will boost Lek's investment in biopharmaceuticals to EUR45mn. Previous projects include the opening of a recombinant protein plant PORT 1 in 2004 and a Biopharmaceuticals Development Centre in 2007.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/65672_slovenia_pharmaceuticals...

Report Table of Contents:

Executive Summary
SWOT Analysis
- Slovenia Pharmaceuticals And Healthcare Industry SWOT
- Slovenia Political SWOT
- Slovenia Economic SWOT
- Slovenia Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Emerging Europe - Regional Pharma Business Environment Ratings for Q310
- Limits of Potential Returns
- Risks to Realisation of Returns
Slovenia - Market Summary
Regulatory Regime
- Recent EU-Wide Regulatory Developments
- Intellectual Property Regime
- IP Deficiencies
- Pricing System
- Reimbursement Policies
- Eurozone Entry
Industry Developments
- Epidemiology
- Table: Disease Burden In CEE
- Healthcare Sector
- Regional Healthcare Collaboration
- Healthcare Provision Developments
- Healthcare Insurance
- Recent Healthcare Insurance Developments
- Healthcare Expenditure
- Clinical Trials
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Slovenia - Economic Activity
- Prescription Market Forecast
- Patented Market Forecast
- Generic Drug Market Forecast
- OTC Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Table: Leading Companies In Slovenia. 2008
Company Monitor
- Indigenous Company Profiles
- Krka
- Lek (Novartis/Sandoz)
- Multinational Company Profiles
- GlaxoSmithKline
- Sanofi-Aventis
- Pfizer
- Novartis
- Merck & Co
Country Snapshot: Slovenia Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market and Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.